| Patient | Paul Robeson |
|---|---|
| Date of birth | 1898-04-09 |
| Identifiers | MRN HR-ML048-SYN-TD; SSN (made up) 000-48-2647 |
| Document date | 1957-04-20 |
| Author | Theodore Bankole-Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review of depression treatment. [S]
Mr. Robeson returns six weeks after starting sertraline. He took 50 mg for two weeks with mild nausea that passed in a week, and after the nurse's phone check he has taken 100 mg for three and a half weeks. He has been to five behavioral activation sessions and has begun short walks and an hour of reading each day, but he still wakes early, has little pleasure, and has not sung. He has had no thoughts of being better off dead for three weeks. He has noticed no rise in energy or reduced need for sleep. He takes every dose and keeps his medicines locked. [S]
| Element | Detail |
|---|---|
| Medicines | Sertraline 50 mg for two weeks, then 100 mg for three and a half weeks; every dose taken |
| Therapy | Five behavioral activation sessions |
| Mood | PHQ-9 19 from 22; no thoughts of death for three weeks |
| Side effects | Nausea in the first week only |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; appetite a little better; weight 99.5 kg |
| Psychiatric | Positive | Low mood and little pleasure; early waking; no thoughts of suicide; no elation |
| Gastrointestinal | Negative | Nausea gone |
| Neurological | Negative | No tremor or headache |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg tablet, one tablet each morning | 50 mg each morning for two weeks | Oral route | 1957-03-12 to 1957-03-25 | completed | S |
| Sertraline 100 mg tablet, one tablet each morning | 100 mg each morning | Oral route | 1957-03-26 to 1957-04-19 | completed | S |
| Sertraline 50 mg tablets, three tablets (150 mg) each morning | 150 mg each morning for two weeks | Oral route | 1957-04-20 to 1957-05-03 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1957-04-20 | Body height | 190 | cm | S |
| 1957-04-20 | Body weight | 99.5 | kg | S |
| 1957-04-20 | Body mass index (BMI) [Ratio] | 27.6 | kg/m2 | S |
| 1957-04-20 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1957-04-20 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1957-04-20 | Heart rate | 72 | /min | S |
| 1957-04-20 | Respiratory rate | 14 | /min | S |
| 1957-04-20 | Body temperature | 36.7 | Cel | S |
| 1957-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1957-04-20 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1957-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 19 | {score} | S |
Vital signs recorded on 1957-04-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Weight 99.5 kg; blood pressure 126/78, pulse 72 |
| Psychiatric | Slowed; constricted affect, a little brighter; logical; no thoughts of suicide |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| About three months of low mood, exhaustion, poor sleep with waking at three in the morning, loss of interest in singing and reading, poor appetite with 5 kg weight loss, and withdrawal from friends, in a man of 58 under sustained political pressure; PHQ-9 22 with thoughts of being better off dead; depression suspected; medical causes being excluded and urgent psychiatric consultation arranged | resolved | confirmed | R53.83 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the psychiatric consultation; anchored to his documented depression and loss of work (D). |
| Major depressive disorder, recurrent, severe, without psychotic features (second episode; structured diagnostic interview; MDQ negative and no past hypomanic or manic episode on interview) | active | confirmed | F33.2 | S — Synthetic modern diagnosis anchored to his documented depression after the 1955 breakdown (D); the bipolar interpretation (R) is addressed and not adopted. |
| Sustained political persecution: passport withheld, concerts and recordings cancelled, income lost, and surveillance by federal agencies; a major and realistic stressor, not a delusion | active | confirmed | Z60.5 | S — Synthetic coding of his documented persecution as a social determinant of his depression. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline and at least monthly during acute treatment (CMID) | Completed today | 19, down 14 percent from 22; item 9 scored 0 |
| Survey | PHQ-9 between visits, rated by the psychologist at each session | At each therapy session | Deferred | Missed: no PHQ-9 was collected about four weeks into treatment; the two-week nurse call checked side effects and safety but not the PHQ-9, and no visit was booked at four weeks. No harm judging by today's score and his safety review. Corrective action: the psychologist now rates the PHQ-9 at each weekly session and reports any rise or positive item 9 the same day |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, locked medicines and the 988 Suicide & Crisis Lifeline | Every visit during active treatment | Completed today | No thoughts of suicide for three weeks; medicines locked; safety plan reviewed |
| Laboratory | Sodium (SSRI or SNRI in an older adult) | Baseline, about four to six weeks after starting, and with symptoms | Completed today | 138 mmol/L, normal |
| Medication safety | Adherence and adverse-effect review | Every visit | Completed today | Every dose taken; nausea in the first week only |
| Medication safety | Adequacy of the antidepressant trial (dose and duration) | At each review: at least four to eight weeks at an adequate dose before judging response | Completed today | Three and a half weeks at 100 mg: not yet an adequate trial; dose raised |
| Medication safety | Watch for hypomania or mixed features after starting or changing an antidepressant | Every visit; repeat the MDQ if features emerge | Completed today | No elation, reduced need for sleep or racing thoughts |
| Referral | Behavioral activation with a psychologist | Weekly for about sixteen sessions | Completed today | Five sessions attended; daily walks and reading scheduled |
| Self-management | Trust, confidentiality and culturally responsive care | Every visit | Completed today | He feels able to speak freely with his therapist |
| Referral | Social work for income and costs | Monthly | Completed today | Meeting the social worker monthly about costs |
Goal progress:
Guideline basis: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Williams DR, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry 2007;64(3):305-315 (2007)
Follow-up: Sertraline 200 mg in two weeks. Review in seven weeks with the PHQ-9 and sodium. Weekly behavioral activation with a PHQ-9 at each session. Call or text 988 at any time in a crisis. Next scheduled visit 1957-06-08: three-month review: no response to an adequate sertraline trial; switch to venlafaxine. [S]